SCHEMBL10215367

SCHEMBL10215367

O=C(O)c1cc(O)c2c(Cl)c(-c3ccccc3)cc(C(F)(F)F)c2n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.38
RBP4 P02753 4/20 0.37
KDM4E B2RXH2 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ENPP1 P22413 1/20 0.35
MRGPRX4 Q96LA9 1/20 0.35
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
DHODH Q02127 2/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C8 P10632 1/20 0.34
CYP2C9 P11712 1/20 0.34
SCN9A Q15858 1/20 0.34
PIK3CA P42336 1/20 0.34
PTGER1 P34995 1/20 0.34
TTR P02766 1/20 0.34
PDGFRB P09619 1/20 0.34
KDR P35968 1/20 0.34
FLT3 P36888 1/20 0.34
TACR1 P25103 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10215370 0.80 RAB9A (0.48) KDM4EHSD17B10LMNAPOLBTHRB
SCHEMBL10215355 0.75 LDHA (0.45) KMORBP4KDM4EHSD17B10DHODH
SCHEMBL6080459 0.72 KDM4E (0.41) KMORBP4KDM4E
SCHEMBL6080071 0.72 KDM4E (0.44) KMOKDM4E
SCHEMBL10215361 0.70 KMO (0.36) KMOKDM4EHSD17B10LMNAPOLB
SCHEMBL6079930 0.69 BRD4 (0.38) KDM4EHSD17B10LMNACYP2C9HPGD
SCHEMBL6591655 0.68 MRGPRX4 (0.47) MRGPRX4PTGER1
SCHEMBL6079850 0.67 CYP3A4 (0.52) KDM4EENPP1DHODHCYP3A4CYP2C8
SCHEMBL6080859 0.67 MCL1 (0.43) KMOKDM4EDHODHCYP3A4CYP2C8
SCHEMBL10215543 0.67 LDHA (0.44) KMORBP4KDM4EHSD17B10DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053148-A1 INHIBITORS OF HEPATITIS C VIRUS GILEAD SCIENCES, INC. (US) 2012-03-01 US disclosed
US-20120053148-A1 INHIBITORS OF HEPATITIS C VIRUS GILEAD SCIENCES, INC. (US) 2012-03-01 US disclosed
WO-2011156610-A2 INHIBITORS OF HEPATITIS C VIRUS GILEAD SCIENCES, INC. (US) 2011-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053148-A1 INHIBITORS OF HEPATITIS C VIRUS HAVCR2, FABP1, EIF2AK2 KMO 4731/4885RBP4 541/4885KDM4E 4201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.